PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Present at the 2011 Wedbush Life Sciences Conference

ROCKVILLE, Md., Aug 16, 2011 (GlobeNewswire via COMTEX) --

Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will be presenting at the 2011 Wedbush Life Sciences: Management Access Conference on August 17, 2011 at 2:25pm at Le Parker Meridien, New York City. A live audio-only webcast link for the presentation can be accessed via the Company website at www.novavax.com under Investors/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Novavax, Inc.

CONTACT: Frederick W. Driscoll
VP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000